J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
Cisco Forecasts Strong Fiscal 2027 Growth as AI Networking Demand Surges 
China Automakers Accelerate Global Expansion as Domestic Car Sales Slump 
Goldman Sachs Eyes Investors for Nvidia’s $500 Billion AI Financing Plan 
Apple Develops China-Specific AI Model With Alibaba as Apple Intelligence Launch Nears 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Super Micro Stock Jumps 19% as AI Server Demand Drives Strong 2027 Outlook 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Bill Ackman’s Pershing Square Returns to Netflix With Major New Stake 
LG, Nvidia Expand AI Partnership With Humanoid Robots, AI Factories 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Anthropic Eyes $6B Decart AI Acquisition Ahead of Mega IPO 
Paramount Weighs CNN Sale as $110B Warner Bros. Discovery Deal Faces Antitrust Fight 
Stripe, Advent Reportedly Pursue $53 Billion PayPal Takeover 
Add as a preferred source on Google
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 01, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the Cowen and Company 37th Annual Health Care Conference in Boston. Chief Executive Officer Mary Szela is scheduled to present on Wednesday, March 8, 2017 at 8:40 a.m. EST.
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
